A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

April 22, 2026

Study Completion Date

April 22, 2026

Conditions
Hematologic Malignancies
Interventions
DRUG

Teclistamab

Teclistamab will be administered subcutaneously.

Trial Locations (15)

296-8602

Kameda Medical Center, Chiba

503-8502

Ogaki Municipal Hospital, Gifu

311-3193

National Hospital Organization Mito Medical Center, Higashiibaraki-gun

650 0047

Kobe City Medical Center General Hospital, Kobe

860-0008

National Hospital Organization Kumamoto Medical Center, Kumamoto

830-0011

Kurume University Hospital, Kurume

603-8151

Kyoto Kuramaguchi Medical Center, Kyoto

399-8701

National Hospital Organization Matsumoto Medical Center, Matsumoto

467 8602

Nagoya City University Hospital, Nagoya

951-8566

Niigata Cancer Center Hospital, Niigata

701-1192

National Hospital Organization Okayama Medical Center, Okayama

541 8567

Osaka International Cancer Institute, Osaka

543-8555

Japanese Red Cross Osaka Hospital, Osaka

739-0696

National Hospital Organization Hiroshima-Nishi Medical Center, Ōtake

150-8935

Japanese Red Cross Medical Center, Shibuya City

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT04696809 - A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter